Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCORE: ALIS-based regimen in newly diagnosed MAC lung infection
jRCT2051220053Completed
- Sponsor
- Insmed Incorporated
- Start
- Mar 2022
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of amikacin liposome inhalation suspension in nontuberculous mycobacterial lung disease (2 arms), sponsored by Insmed Incorporated. Primary endpoint: Change from Baseline in Respiratory Symptom Score at Month 13. Started Mar 2022; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
nontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on jRCT2051220053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220053.